Philip Siberg, CEO of Senzime, presents the Q3 report for 2024.
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Strong sales growth driven by accelerated sensor sales and increased usage of TetraGraph systems, as we continue to win more strategic hospital accounts in the US market.
44,4
78
119
63.9
Annual Report 2023
Growth was driven by milestone new business deals and recurring sales of disposable sensors, as well as new clinical guidelines supporting Senzime’s products.
Download PDFReports and presentations archive
Chief Executive Officer
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.